318 related articles for article (PubMed ID: 21715687)
1. CD28 expressed on malignant plasma cells induces a prosurvival and immunosuppressive microenvironment.
Nair JR; Carlson LM; Koorella C; Rozanski CH; Byrne GE; Bergsagel PL; Shaughnessy JP; Boise LH; Chanan-Khan A; Lee KP
J Immunol; 2011 Aug; 187(3):1243-53. PubMed ID: 21715687
[TBL] [Abstract][Full Text] [Related]
2. CD28-mediated regulation of multiple myeloma cell proliferation and survival.
Bahlis NJ; King AM; Kolonias D; Carlson LM; Liu HY; Hussein MA; Terebelo HR; Byrne GE; Levine BL; Boise LH; Lee KP
Blood; 2007 Jun; 109(11):5002-10. PubMed ID: 17311991
[TBL] [Abstract][Full Text] [Related]
3. CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.
Murray ME; Gavile CM; Nair JR; Koorella C; Carlson LM; Buac D; Utley A; Chesi M; Bergsagel PL; Boise LH; Lee KP
Blood; 2014 Jun; 123(24):3770-9. PubMed ID: 24782505
[TBL] [Abstract][Full Text] [Related]
4. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
5. Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
Tai YT; Cho SF; Anderson KC
Front Immunol; 2018; 9():1822. PubMed ID: 30147691
[TBL] [Abstract][Full Text] [Related]
6. Malignant plasma cell lines express a functional CD28 molecule.
Zhang XG; Olive D; Devos J; Rebouissou C; Ghiotto-Ragueneau M; Ferlin M; Klein B
Leukemia; 1998 Apr; 12(4):610-8. PubMed ID: 9557621
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD28 by bone marrow stromal cells and its involvement in B lymphopoiesis.
Gray Parkin K; Stephan RP; Apilado RG; Lill-Elghanian DA; Lee KP; Saha B; Witte PL
J Immunol; 2002 Sep; 169(5):2292-302. PubMed ID: 12193694
[TBL] [Abstract][Full Text] [Related]
8. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy.
Winter O; Dame C; Jundt F; Hiepe F
J Immunol; 2012 Dec; 189(11):5105-11. PubMed ID: 23169863
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
Klein B; Seckinger A; Moehler T; Hose D
Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
[TBL] [Abstract][Full Text] [Related]
10. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
11. The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
Wang J; De Veirman K; De Beule N; Maes K; De Bruyne E; Van Valckenborgh E; Vanderkerken K; Menu E
Oncotarget; 2015 Dec; 6(41):43992-4004. PubMed ID: 26556857
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
[TBL] [Abstract][Full Text] [Related]
13. The CD28/CTLA-4-B7 signaling pathway is involved in both allergic sensitization and tolerance induction to orally administered peanut proteins.
van Wijk F; Nierkens S; de Jong W; Wehrens EJ; Boon L; van Kooten P; Knippels LM; Pieters R
J Immunol; 2007 Jun; 178(11):6894-900. PubMed ID: 17513738
[TBL] [Abstract][Full Text] [Related]
14. Potential role of CD28-B7 interactions in the growth of myeloma plasma cells.
Kornbluth J
Curr Top Microbiol Immunol; 1995; 194():43-9. PubMed ID: 7534672
[No Abstract] [Full Text] [Related]
15. CD28 Promotes Plasma Cell Survival, Sustained Antibody Responses, and BLIMP-1 Upregulation through Its Distal PYAP Proline Motif.
Rozanski CH; Utley A; Carlson LM; Farren MR; Murray M; Russell LM; Nair JR; Yang Z; Brady W; Garrett-Sinha LA; Schoenberger SP; Green JM; Boise LH; Lee KP
J Immunol; 2015 May; 194(10):4717-28. PubMed ID: 25833397
[TBL] [Abstract][Full Text] [Related]
16. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression.
Shapiro VS; Mollenauer MN; Weiss A
Blood; 2001 Jul; 98(1):187-93. PubMed ID: 11418479
[TBL] [Abstract][Full Text] [Related]
17. An IL-1β-driven neutrophil-stromal cell axis fosters a BAFF-rich protumor microenvironment in individuals with multiple myeloma.
de Jong MME; Fokkema C; Papazian N; Czeti Á; Appelman MK; Vermeulen M; van Heusden T; Hoogenboezem RM; van Beek G; Tahri S; Sanders MA; van de Woestijne PC; Gay F; Moreau P; Büttner-Herold M; Bruns H; van Duin M; Broijl A; Sonneveld P; Cupedo T
Nat Immunol; 2024 May; 25(5):820-833. PubMed ID: 38600356
[TBL] [Abstract][Full Text] [Related]
18. Predicting the impact of combined therapies on myeloma cell growth using a hybrid multi-scale agent-based model.
Ji Z; Su J; Wu D; Peng H; Zhao W; Nlong Zhao B; Zhou X
Oncotarget; 2017 Jan; 8(5):7647-7665. PubMed ID: 28032590
[TBL] [Abstract][Full Text] [Related]
19. HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.
Borsi E; Perrone G; Terragna C; Martello M; Zamagni E; Tacchetti P; Pantani L; Brioli A; Dico AF; Zannetti BA; Rocchi S; Cavo M
Exp Cell Res; 2014 Nov; 328(2):444-55. PubMed ID: 25257607
[TBL] [Abstract][Full Text] [Related]
20. CD28, a marker associated with tumoral expansion in multiple myeloma.
Robillard N; Jego G; Pellat-Deceunynck C; Pineau D; Puthier D; Mellerin MP; Barillé S; Rapp MJ; Harousseau JL; Amiot M; Bataille R
Clin Cancer Res; 1998 Jun; 4(6):1521-6. PubMed ID: 9626472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
